Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 465 participants.

Also called NCT01472185

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 465 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01472185
Other papers using this trial's data
  • Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes Diabetes care, 2015-07 DOI, PubMed 26049552, PMC4477340 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Czechia, Hungary, Poland, Romania, Russia, Serbia, Slovakia, South Africa, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01472185. Randomized; triple masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2013-10 (actual). Results posted on 2014-10-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Ranolazine
Intervention (Drug)
Placebo
Intervention (Behavioral)
Diet
Intervention (Behavioral)
Exercise
Lead sponsor
Gilead Sciences (class: industry)

Record details

Record id
cardio:ct-nct01472185
Content hash
f4eeed8be96317737c02be704c06f070ca9b1e516150d53bc3b6542dcf79b8d4